MNTA hits 12-month high on strong volume, but no news. FWIW, July marks the 5-year anniversary of the FDA’s acceptance of MNTA’s Copaxone ANDA for review (#msg-30621490), which might be a duration the FDA does not wish to exceed.
Also, I updated the MNTA ReadMeFirst yesterday, LOL.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”